Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Holiday destinations for Creature Sweethearts - 2Winter virus season so far is not too bad, but doctors worry about suffering to come
- 3My Excursion to Monetary Autonomy: Awesome ways to save cash
- 4Christmas 2025 skywatching guide: What you can see in the night sky on Dec. 25
- 5Finding the Universe of Computer generated Reality: Individual Encounters
- Step by step instructions to Get the Best Vehicle Rent Arrangement: Insider Tips and Systems
- New electric car registrations rise sharply in Germany in March
- 'The Drama' plot twist, explained: What did Zendaya's character do, and what happens to her wedding?
- Sophie Kinsella, 'Confessions of a Shopaholic' author, dies at 55 after battle with cancer
- 7 Peculiar Ways Of starting Your Imagination: Motivation Has Never Been This Good times
- Israel violated ceasefire with Hezbollah more than 10,000 times, UNIFIL claims
- Find the Historical backdrop of Common liberties: Advancing Equity and Equity Around the world
- Fuel Price Spike Drives Surge in Used EV Sales in Europe
- Insight: Pills, TikTok, weight-loss apps and the consumer-driven future of GLP-1s
